WALL STREET ASSOCIATES - ENANTA PHARMACEUTICALS INC ownership

ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 130 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.

Quarter-by-quarter ownership
WALL STREET ASSOCIATES ownership history of ENANTA PHARMACEUTICALS INC
ValueSharesWeighting
Q4 2016$342,000
+26.2%
10,2000.0%0.23%
+145.7%
Q3 2016$271,000
+20.4%
10,2000.0%0.09%
+2.2%
Q2 2016$225,000
-25.0%
10,2000.0%0.09%
-28.0%
Q1 2016$300,000
-11.0%
10,2000.0%0.12%
+31.6%
Q4 2015$337,000
-8.7%
10,2000.0%0.10%
+33.8%
Q3 2015$369,000
-94.4%
10,200
-93.0%
0.07%
-88.5%
Q2 2015$6,582,000
+41.6%
146,300
-3.6%
0.62%
+41.2%
Q1 2015$4,648,000
-42.3%
151,800
-4.2%
0.44%
-43.1%
Q4 2014$8,055,000
+27.9%
158,400
-0.4%
0.77%
+18.8%
Q3 2014$6,296,000
-33.3%
159,100
-27.4%
0.65%
-19.9%
Q2 2014$9,441,000
+9.0%
219,200
+1.2%
0.81%
+14.7%
Q1 2014$8,662,000
+17.4%
216,600
-19.9%
0.71%
+16.9%
Q4 2013$7,377,000
+26.3%
270,400
+6.1%
0.60%
+11.0%
Q3 2013$5,842,000
+25.5%
254,900
-3.0%
0.54%
+14.7%
Q2 2013$4,654,000262,8000.48%
Other shareholders
ENANTA PHARMACEUTICALS INC shareholders Q2 2016
NameSharesValueWeighting ↓
Krensavage Asset Management, LLC 936,777$53,218,00016.69%
Fairmount Funds Management LLC 316,952$18,006,0006.55%
ARMISTICE CAPITAL, LLC 1,836,000$104,303,0001.77%
Soleus Capital Management, L.P. 182,400$10,362,0001.62%
Portland Global Advisors LLC 62,635$3,558,0000.66%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 40,000$2,263,0000.55%
FARALLON CAPITAL MANAGEMENT LLC 1,995,000$113,336,0000.53%
Yorktown Management & Research Co Inc 10,400$591,0000.44%
Hennion & Walsh Asset Management, Inc. 120,240$6,831,0000.36%
Virtus ETF Advisers LLC 9,599$545,0000.24%
View complete list of ENANTA PHARMACEUTICALS INC shareholders